 LEXINGTON, Mass., Aug. 26, 2021 GLOBE NEWSWIRE -- Agenus Inc. NASDAQ: AGEN, an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that results from a global Phase 2 clinical study of balstilimab monotherapy in recurrentmetastatic cervical cancer were published online in the international peer reviewed journal Gynecologic Oncology 